TY - JOUR
T1 - Clinical relevance of HEp-2 indirect immunofluorescent patterns
T2 - the International Consensus on ANA patterns (ICAP) perspective
AU - Damoiseaux, Jan
AU - Coelho Andrade, Luis Eduardo
AU - Gabriel Carballo, Orlando
AU - Conrad, Karsten
AU - Carvalho Francescantonio, Paulo Luiz
AU - Fritzler, Marvin J.
AU - Garcia de la Torre, Ignacio
AU - Herold, Manfred
AU - Klotz, Werner
AU - Cruvinel, Wilson de Melo
AU - Mimori, Tsuneyo
AU - von Muhlen, Carlos
AU - Satoh, Minoru
AU - Chan, Edward K.
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2019/7
Y1 - 2019/7
N2 - The indirect immunofluorescence assay (IIFA) on HEp-2 cells is widely used for detection of antinuclear antibodies (ANA). The dichotomous outcome, negative or positive, is integrated in diagnostic and classification criteria for several systemic autoimmune diseases. However, the HEp-2 IIFA test has much more to offer: besides the titre or fluorescence intensity, it also provides fluorescence pattern(s). The latter include the nucleus and the cytoplasm of interphase cells as well as patterns associated with mitotic cells. The International Consensus on ANA Patterns (ICAP) initiative has previously reached consensus on the nomenclature and definitions of HEp-2 IIFA patterns. In the current paper, the ICAP consensus is presented on the clinical relevance of the 29 distinct HEp-2 IIFA patterns. This clinical relevance is primarily defined within the context of the suspected disease and includes recommendations for follow-up testing. The discussion includes how this information may benefit the clinicians in daily practice and how the knowledge can be used to further improve diagnostic and classification criteria.
AB - The indirect immunofluorescence assay (IIFA) on HEp-2 cells is widely used for detection of antinuclear antibodies (ANA). The dichotomous outcome, negative or positive, is integrated in diagnostic and classification criteria for several systemic autoimmune diseases. However, the HEp-2 IIFA test has much more to offer: besides the titre or fluorescence intensity, it also provides fluorescence pattern(s). The latter include the nucleus and the cytoplasm of interphase cells as well as patterns associated with mitotic cells. The International Consensus on ANA Patterns (ICAP) initiative has previously reached consensus on the nomenclature and definitions of HEp-2 IIFA patterns. In the current paper, the ICAP consensus is presented on the clinical relevance of the 29 distinct HEp-2 IIFA patterns. This clinical relevance is primarily defined within the context of the suspected disease and includes recommendations for follow-up testing. The discussion includes how this information may benefit the clinicians in daily practice and how the knowledge can be used to further improve diagnostic and classification criteria.
KW - PRIMARY BILIARY-CIRRHOSIS
KW - IDIOPATHIC INFLAMMATORY MYOPATHIES
KW - SYSTEMIC-LUPUS-ERYTHEMATOSUS
KW - PRIMARY SJOGRENS-SYNDROME
KW - CELL NUCLEAR ANTIGEN
KW - CLASSIFICATION CRITERIA
KW - ANTINUCLEAR ANTIBODIES
KW - RHEUMATOLOGY/EUROPEAN LEAGUE
KW - HUMAN AUTOANTIBODIES
KW - HEALTHY-INDIVIDUALS
U2 - 10.1136/annrheumdis-2018-214436
DO - 10.1136/annrheumdis-2018-214436
M3 - (Systematic) Review article
SN - 0003-4967
VL - 78
SP - 879
EP - 889
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 7
ER -